Peripheral neuropathy in patients with systemic rheumatic diseases treated with leflunomide
| Autor: | Wolfgang L. Gross, J Brandt, A C Arlt, C Metzler |
|---|---|
| Rok vydání: | 2005 |
| Předmět: |
Adult
Male inorganic chemicals medicine.medical_specialty Letter Immunology Postmarketing surveillance General Biochemistry Genetics and Molecular Biology Rheumatology Rheumatic Diseases Internal medicine medicine Humans Immunology and Allergy heterocyclic compounds Adverse effect Aged Retrospective Studies Leflunomide business.industry Peripheral Nervous System Diseases Retrospective cohort study Isoxazoles Middle Aged medicine.disease Antirheumatic Agents enzymes and coenzymes (carbohydrates) Peripheral neuropathy Rheumatoid arthritis Female Vasculitis business medicine.drug |
| Zdroj: | Annals of the Rheumatic Diseases. 64:1798-1800 |
| ISSN: | 0003-4967 |
| Popis: | Leflunomide (LEF) was introduced as a new disease modifying antirheumatic drug in 1998. Up to now hepatotoxicity, hypertension, and diarrhoea have been reported as adverse events. Peripheral neuropathy (PNP) has been described in eight patients with rheumatoid arthritis (RA) and psoriatic arthritis.1–3 In the postmarketing surveillance PNP does not appear as a side effect.4 This first retrospective study aimed at evaluating whether LEF might be associated with PNP in a large cohort of patients with inflammatory rheumatic diseases. All inpatients of a primary rheumatology clinic with systemic rheumatic diseases and treatment with LEF between August 1998 and May 2004 were retrospectively screened for a new onset of PNP. Patients with definite reasons for PNP—for example, active vasculitis or collagenosis, diabetes mellitus, lack of vitamins, alcohol abuse, and neoplasms, were excluded. … |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|